Rapidscan Pharma Solutions has received European Union marketing authorization for Rapiscan (regadenoson), a selective coronary vasodilator for use as a pharmacological stress agent in the diagnosis of coronary artery disease.
Rapiscan, a selective A2A adenosine receptor agonist, is administered as a non-weight based bolus injection. The agent simulates the effects of exercise by temporarily increasing blood flow through the arteries of the heart, providing an option for patients unable to exercise adequately for myocardial perfusion studies. Rapiscan requires no dose adjustment for varying body weight, according to the Hawthorne, Calif.-based company.
Rapidscan develops, makes and sells regadenoson, which is sold in the U.S. as Lexiscan by Astellas Pharma. In September 2010, Rapidscan licensed the rights to develop and sell regadenoson from Gilead Sciences for Europe, Japan, Australia, New Zealand and Israel.